{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T22:14:27Z","timestamp":1762899267114},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2016,3,15]],"date-time":"2016-03-15T00:00:00Z","timestamp":1458000000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2016,3,15]],"date-time":"2016-03-15T00:00:00Z","timestamp":1458000000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1038\/pcan.2016.10","type":"journal-article","created":{"date-parts":[[2016,3,15]],"date-time":"2016-03-15T11:21:38Z","timestamp":1458040898000},"page":"139-144","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Chemotherapy for metastatic castrate-sensitive prostate cancer"],"prefix":"10.1038","volume":"19","author":[{"given":"R E","family":"Miller","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C J","family":"Sweeney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,3,15]]},"reference":[{"key":"BFpcan201610_CR1","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1002\/ijc.25516","volume":"127","author":"J Ferlay","year":"2010","unstructured":"Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM . Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893\u20132917.","journal-title":"Int J Cancer"},{"key":"BFpcan201610_CR2","first-page":"293","volume":"1","author":"C Huggins","year":"1941","unstructured":"Huggins C, Hodges CV . Studies in prostate cancer. 1. The effect of castration of oestrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941; 1: 293\u2013297.","journal-title":"Cancer Res"},{"key":"BFpcan201610_CR3","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1002\/cncr.28485","volume":"120","author":"JN Wu","year":"2014","unstructured":"Wu JN, Fish KM, Evans CP, Devere White RW, Dall'Era MA . No improvement noted in overall or cause-specific survival for men presenting with metastatic prostate cancer over a 20-year period. Cancer 2014; 120: 818\u2013823.","journal-title":"Cancer"},{"key":"BFpcan201610_CR4","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/j.juro.2012.06.046","volume":"188","author":"CM Tangen","year":"2012","unstructured":"Tangen CM, Hussain MH, Higano CS, Eisenberger MA, Small EJ, Wilding G et al. Improved overall survival trends of men with newly diagnosed M1 prostate cancer: a SWOG phase III trial experience (S8494, S8894 and S9346). J Urol 2012; 188: 1164\u20131169.","journal-title":"J Urol"},{"key":"BFpcan201610_CR5","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1056\/NEJMoa1503747","volume":"373","author":"CJ Sweeney","year":"2015","unstructured":"Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. New Engl J Med 2015; 373: 737\u2013746.","journal-title":"New Engl J Med"},{"key":"BFpcan201610_CR6","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","volume":"364","author":"JS de Bono","year":"2011","unstructured":"de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L et al. Abiraterone and increased survival in metastatic prostate cancer. New Engl J Med 2011; 364: 1995\u20132005.","journal-title":"New Engl J Med"},{"key":"BFpcan201610_CR7","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","volume":"376","author":"JS de Bono","year":"2010","unstructured":"de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010; 376: 1147\u20131154.","journal-title":"Lancet"},{"key":"BFpcan201610_CR8","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJMoa1001294","volume":"363","author":"PW Kantoff","year":"2010","unstructured":"Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. New Engl J Med 2010; 363: 411\u2013422.","journal-title":"New Engl J Med"},{"key":"BFpcan201610_CR9","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa1213755","volume":"369","author":"C Parker","year":"2013","unstructured":"Parker C, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fossa SD et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. New Engl J Med 2013; 369: 213\u2013223.","journal-title":"New Engl J Med"},{"key":"BFpcan201610_CR10","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","volume":"367","author":"HI Scher","year":"2012","unstructured":"Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. New Engl J Med 2012; 367: 1187\u20131197.","journal-title":"New Engl J Med"},{"key":"BFpcan201610_CR11","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1056\/NEJMoa040720","volume":"351","author":"IF Tannock","year":"2004","unstructured":"Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. New Engl J Med 2004; 351: 1502\u20131512.","journal-title":"New Engl J Med"},{"key":"BFpcan201610_CR12","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3322\/caac.21166","volume":"63","author":"R Siegel","year":"2013","unstructured":"Siegel R, Naishadham D, Jemal A . Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11\u201330.","journal-title":"CA Cancer J Clin"},{"key":"BFpcan201610_CR13","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1002\/cncr.11635","volume":"98","author":"DC Miller","year":"2003","unstructured":"Miller DC, Hafez KS, Stewart A, Montie JE, Wei JT . Prostate carcinoma presentation, diagnosis, and staging: an update form the National Cancer Data Base. Cancer 2003; 98: 1169\u20131178.","journal-title":"Cancer"},{"key":"BFpcan201610_CR14","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.urolonc.2005.09.003","volume":"24","author":"CJ Ryan","year":"2006","unstructured":"Ryan CJ, Elkin EP, Small EJ, Duchane J, Carroll P . Reduced incidence of bony metastasis at initial prostate cancer diagnosis: data from CaPSURE. Urol Oncol 2006; 24: 396\u2013402.","journal-title":"Urol Oncol"},{"key":"BFpcan201610_CR15","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/j.eururo.2012.02.054","volume":"61","author":"MM Center","year":"2012","unstructured":"Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O et al. International variation in prostate cancer incidence and mortality rates. Eur Urol 2012; 61: 1079\u20131092.","journal-title":"Eur Urol"},{"key":"BFpcan201610_CR16","doi-asserted-by":"publisher","first-page":"7","DOI":"10.4103\/1477-3163.94025","volume":"11","author":"J Cullen","year":"2012","unstructured":"Cullen J, Elsamanoudi S, Brassell SA, Chen Y, Colombo M, Srivastava A et al. The burden of prostate cancer in Asian nations. J Carcinog 2012; 11: 7.","journal-title":"J Carcinog"},{"key":"BFpcan201610_CR17","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1056\/NEJMoa041318","volume":"351","author":"DP Petrylak","year":"2004","unstructured":"Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr., Jones JA, Taplin ME et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. New Engl J Med 2004; 351: 1513\u20131520.","journal-title":"New Engl J Med"},{"key":"BFpcan201610_CR18","doi-asserted-by":"publisher","first-page":"E520","DOI":"10.5489\/cuaj.2076","volume":"8","author":"RR Zielinski","year":"2014","unstructured":"Zielinski RR, Azad AA, Chi KN, Tyldesely S . Population-based impact on overall survival after the introduction of docetaxel as standard therapy for metastatic castration resistant prostate cancer. Can Urol Assoc J 2014; 8: E520\u2013E523.","journal-title":"Can Urol Assoc J"},{"key":"BFpcan201610_CR19","doi-asserted-by":"publisher","first-page":"2943","DOI":"10.1093\/annonc\/mds119","volume":"23","author":"J Mezynski","year":"2012","unstructured":"Mezynski J, Pezaro C, Bianchini D, Zivi A, Sandhu S, Thompson E et al. Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance? Ann Oncol 2012; 23: 2943\u20132947.","journal-title":"Ann Oncol"},{"key":"BFpcan201610_CR20","doi-asserted-by":"publisher","first-page":"3821","DOI":"10.1016\/j.ejca.2013.09.026","volume":"49","author":"RJ van Soest","year":"2013","unstructured":"van Soest RJ, van Royen ME, de Morree ES, Moll JM, Teubel W, Wiemer EA et al. Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer. Eur Cancer 2013; 49: 3821\u20133830.","journal-title":"Eur Cancer"},{"key":"BFpcan201610_CR21","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1002\/pros.22844","volume":"74","author":"DL Suzman","year":"2014","unstructured":"Suzman DL, Luber B, Schweizer MT, Nadal R, Antonarakis ES . Clinical activity of enzalutamide versus docetaxel in men with castration-resistant prostate cancer progressing after abiraterone. Prostate 2014; 74: 1278\u20131285.","journal-title":"Prostate"},{"key":"BFpcan201610_CR22","doi-asserted-by":"publisher","first-page":"4905","DOI":"10.1158\/1078-0432.CCR-04-2140","volume":"11","author":"BJ Eigl","year":"2005","unstructured":"Eigl BJ, Eggener SE, Baybik J, Ettinger S, Chi KN, Nelson C et al. Timing is everything: preclinical evidence supporting simultaneous rather than sequential chemohormonal therapy for prostate cancer. Clin Cancer Res 2005; 11: 4905\u20134911.","journal-title":"Clin Cancer Res"},{"key":"BFpcan201610_CR23","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1158\/1078-0432.CCR-05-1388","volume":"12","author":"Y Tang","year":"2006","unstructured":"Tang Y, Khan MA, Goloubeva O, Lee DI, Jelovac D, Brodie AM et al. Docetaxel followed by castration improves outcomes in LNCaP prostate cancer-bearing severe combined immunodeficient mice. Clin Cancer Res 2006; 12: 169\u2013174.","journal-title":"Clin Cancer Res"},{"key":"BFpcan201610_CR24","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1016\/S0022-5347(05)68191-8","volume":"162","author":"TM de Reijke","year":"1999","unstructured":"de Reijke TM, Keuppens FI, Whelan P, Kliment J, Robinson MR, Rea LA et al. Orchiectomy and orchiectomy plus mitomycin C for metastatic prostate cancer in patients with poor prognosis: the final results of a European Organization for Research in Cancer Therapy Genitourinary Group Trial. J Urol 1999; 162: 1658\u20131664.","journal-title":"J Urol"},{"key":"BFpcan201610_CR25","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/S0090-4295(96)00496-7","volume":"49","author":"RA Janknegt","year":"1997","unstructured":"Janknegt RA, Boon TA, van de Beek C, Grob P . Combined hormono\/chemotherapy as primary treatment for metastatic prostate cancer: a randomized, multicenter study of orchiectomy alone versus orchiectomy plus estramustine phosphate. The Dutch Estracyt Study Group. Urology 1997; 49: 411\u2013420.","journal-title":"Urology"},{"key":"BFpcan201610_CR26","doi-asserted-by":"publisher","first-page":"5936","DOI":"10.1200\/JCO.2007.15.9830","volume":"26","author":"RE Millikan","year":"2008","unstructured":"Millikan RE, Wen S, Pagliaro LC, Brown MA, Moomey B, Do KA et al. Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer. J Clin Oncol 2008; 26: 5936\u20135942.","journal-title":"J Clin Oncol"},{"key":"BFpcan201610_CR27","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1111\/j.1442-2042.2004.t01-1-00748.x","volume":"11","author":"M Noguchi","year":"2004","unstructured":"Noguchi M, Noda S, Yoshida M, Ueda S, Shiraishi T, Itoh K et al. Chemohormonal therapy as primary treatment for metastatic prostate cancer: a randomized study of estramustine phosphate plus luteinizing hormone-releasing hormone agonist versus flutamide plus luteinizing hormone-releasing hormone agonist. Int J Urol 2004; 11: 103\u2013109.","journal-title":"Int J Urol"},{"key":"BFpcan201610_CR28","first-page":"81","volume":"32","author":"K Pummer","year":"1997","unstructured":"Pummer K, Lehnert M, Stettner H, Hubmer G . Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer. Eur Urol 1997; 32: 81\u201385.","journal-title":"Eur Urol"},{"key":"BFpcan201610_CR29","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1046\/j.1464-410x.2000.00894.x","volume":"86","author":"J Wang","year":"2000","unstructured":"Wang J, Halford S, Rigg A, Roylance R, Lynch M, Waxman J . Adjuvant mitozantrone chemotherapy in advanced prostate cancer. BJU Int 2000; 86: 675\u2013680.","journal-title":"BJU Int"},{"key":"BFpcan201610_CR30","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/S1470-2045(12)70560-0","volume":"14","author":"G Gravis","year":"2013","unstructured":"Gravis G, Fizazi K, Joly F, Oudard S, Priou F, Esterni B et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol 2013; 14: 149\u2013158.","journal-title":"Lancet Oncol"},{"key":"BFpcan201610_CR31","doi-asserted-by":"publisher","first-page":"abstr 5001","DOI":"10.1200\/jco.2015.33.15_suppl.5001","volume":"33","author":"NDSM James","year":"2015","unstructured":"James ND SM, Mason MD, Clarke NW, Dearnaley DP, Spears MR, Millman R et al. STAMPEDE Investigators;. Docetaxel and\/or zoledronic acid for hormone-na\u00efve prostate cancer: First overall survival results from STAMPEDE (NCT00268476). J Clin Oncol 2015; 33: abstr 5001.","journal-title":"J Clin Oncol"},{"key":"BFpcan201610_CR32","doi-asserted-by":"publisher","first-page":"abstract 140","DOI":"10.1200\/jco.2015.33.7_suppl.140","volume":"33","author":"GB Gravis","year":"2015","unstructured":"Gravis GB, JolyF, Oudard S, Albiges L, Priou F, Latorzeff I et al. Androgen deprivation therapy(ADT) plus docetaxel (D) versus ADT alone for hormone-na\u00efve metastatic prostate cancer (PCa): long-term analysis of the GETUG-AFU 15 phase III trial. J Clin Oncol 2015; 33: abstract 140.","journal-title":"J Clin Oncol"},{"key":"BFpcan201610_CR33","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/1745-6215-10-39","volume":"10","author":"MR Sydes","year":"2009","unstructured":"Sydes MR, Parmar MK, James ND, Clarke NW, Dearnaley DP, Mason MD et al. Issues in applying multi-arm multi-stage methodology to a clinical trial in prostate cancer: the MRC STAMPEDE trial. Trials 2009; 10: 39.","journal-title":"Trials"},{"key":"BFpcan201610_CR34","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/S0022-5347(05)64059-1","volume":"169","author":"TR Glass","year":"2003","unstructured":"Glass TR, Tangen CM, Crawford ED, Thompson I . Metastatic carcinoma of the prostate: identifying prognostic groups using recursive partitioning. J Urol 2003; 169: 164\u2013169.","journal-title":"J Urol"},{"key":"BFpcan201610_CR35","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1056\/NEJM198908173210702","volume":"321","author":"ED Crawford","year":"1989","unstructured":"Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. New Engl J Med 1989; 321: 419\u2013424.","journal-title":"New Engl J Med"},{"key":"BFpcan201610_CR36","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1056\/NEJM199810083391504","volume":"339","author":"MA Eisenberger","year":"1998","unstructured":"Eisenberger MA, Blumenstein BA, Crawford ED, Miller G, McLeod DG, Loehrer PJ et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. New Engl J Med 1998; 339: 1036\u20131042.","journal-title":"New Engl J Med"},{"key":"BFpcan201610_CR37","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1056\/NEJMoa1212299","volume":"368","author":"M Hussain","year":"2013","unstructured":"Hussain M, Tangen CM, Berry DL, Higano CS, Crawford ED, Liu G et al. Intermittent versus continuous androgen deprivation in prostate cancer. New Engl J Med 2013; 368: 1314\u20131325.","journal-title":"New Engl J Med"},{"key":"BFpcan201610_CR38","doi-asserted-by":"publisher","first-page":"E70","DOI":"10.1111\/bju.12717","volume":"114","author":"C Tait","year":"2014","unstructured":"Tait C, Moore D, Hodgson C, Brown M, Morris T, Growcott J et al. Quantification of skeletal metastases in castrate-resistant prostate cancer predicts progression-free and overall survival. BJU Int 2014; 114: E70\u2013E73.","journal-title":"BJU Int"},{"key":"BFpcan201610_CR39","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1093\/annonc\/mdv257","volume":"26","author":"S Gillessen","year":"2015","unstructured":"Gillessen S, Omlin A, Attard G, de Bono JS, Efstathiou E, Fizazi K et al. Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Ann Oncol 2015; 26: 1589\u20131604.","journal-title":"Ann Oncol"},{"key":"BFpcan201610_CR40","doi-asserted-by":"publisher","first-page":"S719","DOI":"10.1016\/S0959-8049(16)31941-4","volume":"51","author":"C. Vale","year":"2015","unstructured":"Vale CRL, Tierney JF, Albiges L, Clarke NW, Fisher DJ, Fizazi K et al. What is the current evidence for adding docetaxel or bisphosphonates to androgen deprivation therapy (ADT) in men with hormone sensitive prostate cancer? A systematic review and meta-analyses. Eur J Cancer 2015; 51: 20LBA.","journal-title":"European Journal of Cancer"}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/pcan201610.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/pcan201610","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/pcan201610.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T21:06:53Z","timestamp":1648674413000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/pcan201610"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,15]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["BFpcan201610"],"URL":"https:\/\/doi.org\/10.1038\/pcan.2016.10","relation":{},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,15]]},"assertion":[{"value":"18 October 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2015","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2015","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2016","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"CJS has consultancy with honoraria for Astellas, BIND therapeutics, Sanofi, Janssen, Genentech and Bayer. The remaining author declares no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}